ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • Featured Industry Events
  • ATTENDEE MAP & PHOTOS
  • About Us
  • Register Now
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • Featured Industry Events
  • ATTENDEE MAP & PHOTOS
  • About Us
  • Register Now
loading...
Home toxicity

Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

Mario Lacouture
on: September 17, 2021In: Supportive & Palliative Care
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

Mario Lacouture, MD, is director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center and specializes in the dermatologic side effects of cancer treatment. He is the founder of the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary program bringing together pat... Read more


Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

on: February 11, 2020In: Systemic, Targeted, & Immune Therapies
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With NSCLC

This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on patients with poor performance status.   […] Read more

IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy